Tenox contains amlodipine, an antihypertensive and vasodilator agent, and is registered in 13 countries concentrated across Central and Eastern Europe with a small additional presence further afield. The brand is used in the management of hypertension and angina pectoris, two cardiovascular conditions where amlodipine is a long-established treatment option internationally.
Amlodipine is classified within a group of medications described in the structured data on this page as antihypertensive, hypotensive, antianginal, antispasmodic, and vasodilator. In practical terms, it is prescribed both for the long-term control of elevated blood pressure and for the prevention of angina episodes in patients with stable ischaemic heart disease. The full list of registered indications recognised in the markets where Tenox is sold is shown in the structured section further down this page.
The country footprint for Tenox leans heavily into Central and Eastern Europe and the Balkans — markets where it is available include Poland, Russia, Hungary, Serbia, and Singapore, the latter being the principal outlier from the regional cluster. Travellers and expatriates moving outside this footprint will generally not find Tenox by name on pharmacy shelves, but amlodipine itself is one of the most widely distributed cardiovascular molecules in the world and circulates under many different brand names in essentially every regulated market.
Other medications in the same broader cardiovascular class are also available globally under various molecules and brand names, and a local pharmacist can identify what is stocked in a given country. Decisions about starting amlodipine, substituting Tenox for another product, or adjusting an existing regimen belong with a healthcare provider familiar with the patient's cardiovascular history.
Incompatibilities
None stated.
Preclinical safety data
Reproductive toxicology
Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.
Impairment of fertility
There was no effect on the fertility of rats treated with Tenox (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with Tenox besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.
Carcinogenesis, mutagenesis
Rats and mice treated with Tenox in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.
Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.
*Based on patient weight of 50 kg
Special precautions for disposal and other handling
No special requirements.